STRATEGIC BRIEFINGS
In-depth analysis of pharmaceutical formulation challenges and how AI agents inform drug development workflows, powered by real regulatory data.
The EU Just Made You Pay 80% to Filter Your Own Drug Out of the Water
On 11 May 2026 the EU added pharmaceutical substances to its water-pollutant lists. A separate directive already decided producers finance at least 80% of the cleanup. Environmental fate is now a cost and market-access question, not a Module 1.6 formality.
The GLP-1 Shortage Didn't End. It Moved to the Autoinjector.
FDA's move to strike GLP-1s from the 503B bulks list shifts the bottleneck from drug substance to device. Inside the silicone-oil, glass-delamination, and COP-barrel problem, and the extractables and leachables qualification that now gates every prefilled syringe and autoinjector.
21 ADCs Are Approved. Your Plant Still Cannot Safely Weigh the Payload.
ADC payloads carry occupational exposure limits below 50 ng/m3, sometimes near 1 ng/m3. The OEL, not the dose or the route, decides facility design and capex. Here is the science, the 2026 procurement reality, and how DeepC derives a defensible OEL and OEB tier.
ICH Just Wrote the First Global Rulebook for Leachables. Your US Comments Closed January 30.
Your Cancer Drug Has a Five-Day Shelf Life. Curium Just Bid $7 Billion on Who Controls the Atoms.
The FDA Just Cleared a Bispecific and an Anti-CD38 Antibody in One Myeloma Regimen. Now Your Formulation Has to Keep Both Folded.
Their Gene Therapy Worked. The FDA Said No Anyway.
303 Warning Letters in One Year. The Cleaning Limit FDA Stopped Accepting.
580,844 Bottles of a 1976 Pill, Pulled Over a Number in Nanograms
Oncology Formulation Is a $256 Billion Problem. AACR 2026 Shows Who's Solving It.
3.1 Million Eye Drops Recalled. The GMP Crisis Nobody Fixed.
100% Tariffs on Pharma Imports. Your Formulation Has 120 Days.
98% of Drugs Cannot Cross the Blood Brain Barrier. Denali Just Got One Through.
AI Virtual Screening Hits 750x the Rate of Your HTS Lab. At 90% Lower Cost.
400,000 Patients Switched to a Pill in Ten Weeks. Your Injectable Is Next.
Novo Nordisk Failed to Report Three Deaths on Ozempic. AI Would Have Caught Them.
Google Just Built the Best Drug Design AI in History. You Can't Use It.
Your AI Can Design a Molecule. It Can't Formulate a Drug.
FDA and EMA Just Agreed on AI Rules. Here's What Changes for Drug Development.
70% of Your API Comes from Overseas, and Washington Just Noticed
$300 Billion in Pharma Revenue Loses Patent Protection by 2030
82 Biosimilars Approved and Your Reference Product Is Next
300 Million Patients, 5% Treated: The AI Opportunity in Rare Disease
Cocrystal Screening Has a Math Problem
GLP-1's Cold Chain Nightmare Is Becoming a Gold Mine
AI Validation Is Eating Your R&D Budget
High-Concentration Biologics Are Hitting the Wall
Half Your Tech Transfers Are Failing:Here's Why
You're Virtualizing Everything Except Your Drug
Half Your Clinical Data Is Going Unanalyzed
90% of Molecules Fail Before They Reach Their Target
70 to 90% of Your Pipeline Can't Dissolve
Lipid Nanoparticles Are Breaking the Code
Your Stability Testing Is Costing You Years
CMC Changes Are Creating Drug Shortages
Human Brains Can't Optimize What Machines Can See
The FDA's Own Data Is Your Untapped Competitive Advantage
The Polymer That Saves Your Drug Is Hiding in Plain Sight
You Won't Find Your Blocking Patents Until It's Too Late
One Company Just Did 3.6 Million Experiments in 25 Shots
Your Formulation Team Is Operating Blind
Your API Synthesis Generates 100kg of Waste Per Kilogram of Drug
320 Drug Shortages and Counting: The Batch Manufacturing Breaking Point
Peer-reviewed work
Read our publications
Original research from the DeepCeutix team across pharmaceutical AI, formulation science, and regulatory intelligence.

